Nanotoxicity and the importance of being earnest

Advanced Drug Delivery Reviews

Volumn 64, Issue 15, 2012, Pages 1661-1662

  Vorup Jensen, Thomas ^a   Peer, Dan ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON NANOTUBE; CD11B ANTIGEN; CD14 ANTIGEN; CD18 ANTIGEN; GLYCOPROTEIN P 15095; INTEGRIN; LIPOSOME; NANOPARTICLE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; COMPLEMENT SYSTEM; CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; EDITORIAL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LIPOSOMAL DELIVERY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; NANOANALYSIS; NANOFABRICATION; NANOMEDICINE; NANOTOXICOLOGY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN RNA BINDING; RISK ASSESSMENT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURFACE PROPERTY;

DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84869182375     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.002     Document Type: Editorial

References (39)

1. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
2. Vorup-Jensen T., Boesen T. Protein ultrastructure and the nanoscience of complement activation. Adv. Drug Deliv. Rev. 2011, 63:1008-1019.
3. Lynch I., Dawson K.A., Linse S. Detecting cryptic epitopes created by nanoparticles. Sci. STKE 2006, 2006:e14.
4. Bhatia V.K., Hatzakis N.S., Stamou D. A unifying mechanism accounts for sensing of membrane curvature by BAR domains, amphipathic helices and membrane-anchored proteins. Semin. Cell Dev. Biol. 2010, 21:381-390.
5. Pedersen M.B., Zhou X., Larsen E.K., Sorensen U.S., Kjems J., Nygaard J.V., Nyengaard J.R., Meyer R.L., Boesen T., Vorup-Jensen T. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 2010, 184:1931-1945.
6. Karmali P.P., Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Deliv. 2011, 8:343-357.
7. Simberg D., Park J.H., Karmali P.P., Zhang W.M., Merkulov S., McCrae K., Bhatia S.N., Sailor M., Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
8. Toropov A.A., Toropova A.P., Benfenati E., Gini G., Puzyn T., Leszczynska D., Leszczynski J. Novel application of the CORAL software to model cytotoxicity of metal oxide nanoparticles to bacteria Escherichia coli. Chemosphere 2012, 89:1098-1102.
9. Gajewicz A., Rasulev B., Dinadayalane T.C., Urbaszek P., Puzyn T., Leszczynska D., Leszczynski J. Advancing risk assessment of engineered nanomaterials: application of computational approaches. Adv. Drug Deliv. Rev. 2012, (ADR12309).
10. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52:481-503.
11. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J. Autoimmun. 2010, 34:J234-J246.
12. Tabet L., Bussy C., Amara N., Setyan A., Grodet A., Rossi M.J., Pairon J.C., Boczkowski J., Lanone S. Adverse effects of industrial multiwalled carbon nanotubes on human pulmonary cells. J. Toxicol. Environ. Health A 2009, 72:60-73.
13. Elgrabli D., Abella-Gallart S., Robidel F., Rogerieux F., Boczkowski J., Lacroix G. Induction of apoptosis and absence of inflammation in rat lung after intratracheal instillation of multiwalled carbon nanotubes. Toxicology 2008, 253:131-136.
14. Boczkowski J., Lanone S. Respiratory toxicities of nanomaterials - a focus on carbon nanotubes. Adv. Drug Deliv. Rev. 2012, (ADR12306).
15. Moghimi S.M., Hunter A.C. Complement monitoring of carbon nanotubes. Nat. Nanotechnol. 2010, 5:382. (author reply 382-383).
16. Andersen A.J., Hashemi S.H., Andresen T.L., Hunter A.C., Moghimi S.M. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 2009, 5:364-372.
17. Andersen A.J., Wibroe P.P., Moghimi S.M. Perspectives on carbon nanotube-mediated adverse immune effects. Adv. Drug Deliv. Rev. 2012, (ADR12298).
18. Szebeni J., Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res. 2009, 19:85-90.
19. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
20. Szebeni J., Bedocs P., Csukas D., Rosivall L., Bunger R., Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv. Drug Deliv. Rev. 2012, (ADR12329).
21. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 2010, 31:6867-6875.
22. Ballarin-Gonzalez B., Howard K.A. Polyplex-based delivery of RNAi therapeutics: adverse effects and solutions. Adv. Drug Deliv. Rev. 2012, (ADR 12328).
23. Howard K.A. Delivering the goods: realizing the clinical potential of RNAi. Nanomedicine (Lond.) 2009, 4:595-598.
24. Barros S.A., Gollob J.A. Toxicity profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 2012, (ADR12319).
25. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2012, (ADR12332).
26. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
27. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic lipids activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 2012, (ADR12304).
28. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
29. Vorup-Jensen T. On the roles of polyvalent binding in immune recognition: perspectives in the nanoscience of immunology and the immune response to nanomedicines. Adv. Drug Deliv. Rev. 2012, (ADR12314).
30. Degn S.E., Jensenius J.C., Thiel S. Disease-causing mutations in genes of the complement system. Am. J. Hum. Genet. 2011, 88:689-705.
31. Kutikhin A.G. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum. Immunol. 2011, 72:1095-1116.
32. S.M. Moghimi, P.P. Wibroe, S.Y. Helvig, Z.S. Farhangrazi, A.C. Hunter, Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward, Adv. Drug Deliv. Rev. (in press). http://dx.doi.org/10.1016/j.addr.2012.05.010.
33. Moghimi S.M., Peer D., Langer R. Reshaping the future of nanopharmaceuticals: ad iudicium. ACS Nano 2011, 5:8454-8458.
34. Litvak-Greenfeld D., Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv. Drug Deliv. Rev. 2012, (ADR12308).
35. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 2011, 44:979-989.
36. Jaganathan H., Godin B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv. Drug Deliv. Rev. 2012, (ADR12303).
37. Lokanathan A.R., Zhang S., Regina V.R., Cole M.A., Ogaki R., Dong M., Besenbacher F., Meyer R.L., Kingshott P. Mixed poly (ethylene glycol) and oligo (ethylene glycol) layers on gold as nonfouling surfaces created by backfilling. Biointerphases 2011, 6:180-188.
38. Andersen T.E., Palarasah Y., Skjodt M.O., Ogaki R., Benter M., Alei M., Kolmos H.J., Koch C., Kingshott P. Decreased material-activation of the complement system using low-energy plasma polymerized poly(vinyl pyrrolidone) coatings. Biomaterials 2011, 32:4481-4488.
39. Koegler P., Clayton A., Thissen H., Santos G.N., Kingshott P. The influence of nanostructured materials on biointerfacial interactions. Adv. Drug Deliv. Rev. 2012, (ADR12312).